There are currently 970 clinical trials in Salt Lake City, Utah looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Utah, Huntsman Cancer Institute/University of Utah, Huntsman Cancer Institute and LDS Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
NCT04644770
Recruiting
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s) in participants with metastatic hormone-sensitive prostate cancer (mHSPC) in Part 4.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Prostatic Neoplasms, Adenocarcinoma
Register for Updates
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515
Recruiting
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Utah Cancer Specialists, Salt Lake City, Utah
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
NCT06070350
Recruiting
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/27/2025
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Hemorrhagic Shock, Trauma Injury
Register for Updates
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT03331198
Recruiting
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah +1 locations
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Register for Updates
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571
Recruiting
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Register for Updates
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
NCT06653842
Recruiting
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/27/2025
Locations: University of Utah Health, Salt Lake City, Utah
Conditions: Cutaneous Venous Malformations
Register for Updates
Couples Health Aging, Rhythms and Sleep Study
NCT05952284
Recruiting
Alzheimer's disease and related dementias (ADRD), including mild cognitive impairment (MCI), are becoming among the most prevalent causes of disability, death and healthcare costs worldwide. Sleep and circadian rhythm disturbances are common among individuals with MCI as well as their spouses/ partners and may increase risk of the development of ADRD in both patients and partners. This is the first study to systematically investigate sleep as a shared health behavior within couples in which one... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/27/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Aging, Memory Loss
Register for Updates
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
NCT04576117
Recruiting
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth... Read More
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
03/26/2025
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Recurrent Low Grade Astrocytoma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Recurrent WHO Grade 2 Glioma, Refractory WHO Grade 1 Glioma
Register for Updates
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
NCT05468697
Recruiting
The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 1004), Salt Lake City, Utah
Conditions: Renal Cell Carcinoma
Register for Updates
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Research Site, Salt Lake City, Utah
Conditions: Viral Lung Infection and Acute Respiratory Failure
Register for Updates
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT03871257
Recruiting
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplat... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
03/26/2025
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Register for Updates
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
NCT06524739
Recruiting
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 \[COVID-19\] POTS \[post-COVID-POTS\]).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Bateman Horne Center, Salt Lake City, Utah
Conditions: Post-COVID Postural Orthostatic Tachycardia Syndrome
Register for Updates